Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference32 articles.
1. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105–18.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): multiple myeloma (version 1.2023). 2022. http://www.nccn.org. Accessed 17 Nov 2022.
3. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–22.
4. Scott K, Hayden PJ, Will A, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:CD010816.
5. Hu B, Zhou Q, Hu YY, et al. Efficacy and safety of once-weekly versus twice-weekly bortezomib in patients with hematologic malignancies: a meta-analysis with trial sequential analysis. Pharmacotherapy. 2019;39(6):697–708.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献